Stockscreener 앱 받기
5.15
8.19%
0.39
전일 마감가:
$4.76
열려 있는:
$4.77
하루 거래량:
185.13K
Relative Volume:
1.05
시가총액:
$43.84M
수익:
$120.77M
순이익/손실:
$32.69M
주가수익비율:
1.767
EPS:
2.9146
순현금흐름:
$-50.94M
1주 성능:
+11.96%
1개월 성능:
+5.75%
6개월 성능:
-56.43%
1년 성능:
-32.86%
1일 변동 폭
$4.72
$5.26
1주일 범위
$4.63
$5.26
52주 변동 폭
$3.92
$19.14
아타라 Stock (ATRA) Company Profile
명칭
Atara Biotherapeutics Inc
전화
805-623-4211
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
5.15 | 43.84M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
아타라 Stock (ATRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-20 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-07-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-05-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 개시 | Evercore ISI | Outperform |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-09-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-06-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-05-23 | 개시 | Stifel | Buy |
| 2019-01-23 | 개시 | Mizuho | Buy |
| 2018-04-10 | 개시 | JP Morgan | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2018-03-05 | 재확인 | Jefferies | Buy |
| 2018-02-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-01-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
아타라 주식(ATRA)의 최신 뉴스
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - ChartMill
ATRA DEADLINE NOTICE: Atara Biotherapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 22, 2026 - ACCESS Newswire
ATRA CLASS ACTION REMINDERGet in Touch With Robbins LLP Today For Information About Your Against Atara Biotherapeutics, Inc. - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit - lincolnjournal.com
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit - GlobeNewswire Inc.
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA - ChartMill
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
ATRA Q1'26 Earnings: EPS estimate is (0.33) USD - TradingView
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, Global Investor Counsel, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
2026-05-03 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - The Malaysian Reserve
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus
Atara Biotherapeutics Receives Nasdaq Non-Compliance Delisting Notice - TipRanks
Atara Biotherapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Atara Biotherapeutics (NASDAQ: ATRA) faces Nasdaq $50M market value compliance deadline - Stock Titan
ATRA Deadline Alert: The Gross Law Firm Reminds Atara - GlobeNewswire
Press releases provided by CNW - Techaeris
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Pomerantz LLP Files Investor Lawsuit Against Atara Biotherapeutics, Inc. – ATRA - ACCESS Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Acti - GuruFocus
Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
ATRA Stock Price, Quote & Chart | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Atara - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Dead - GuruFocus
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. LawsuitATRA - Barchart
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
2026-04-28 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on Atara Biotherapeutics, - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
2026-04-27 | ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionATRA - TMX Newsfile
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with ... - Black Hills Pioneer
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - Scott Coop
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionATRA - ACCESS Newswire
아타라 (ATRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):